{"transactions":[{"id":2479580,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127918,"kind":"organization","name":"MILLENNIUM PHARMACEUTICALS INC","position":3,"cik":"0001002637","reported_name":"MILLENNIUM PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113074,"kind":"organization","name":"Takeda Ventures, Inc.","position":4,"cik":"0001771657","reported_name":"Takeda Ventures, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-09T06:04:25.000Z","date":"2021-12-08","kind":"sale","acquired":false,"shares":110338,"price":18.03,"value":1989394.14,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Reflects the weighted average sale price.  This transaction was executed in multiple trades at prices ranging from $18.00 to $18.47.  Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc.  Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein."}],"balance_after":6120124,"source":{"system":"sec-edgar","filing":"0001395064-21-000248","document":"wf-form4_163904785164853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1002637/000139506421000248/wf-form4_163904785164853.xml","form_type":"4"}},{"id":2479579,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127918,"kind":"organization","name":"MILLENNIUM PHARMACEUTICALS INC","position":3,"cik":"0001002637","reported_name":"MILLENNIUM PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113074,"kind":"organization","name":"Takeda Ventures, Inc.","position":4,"cik":"0001771657","reported_name":"Takeda Ventures, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-09T06:04:25.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":58190,"price":19.5,"value":1134705.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the weighted average sale price.  This transaction was executed in multiple trades at prices ranging from $19.00 to $19.88.  Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc.  Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein."}],"balance_after":6230462,"source":{"system":"sec-edgar","filing":"0001395064-21-000248","document":"wf-form4_163904785164853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1002637/000139506421000248/wf-form4_163904785164853.xml","form_type":"4"}},{"id":2479578,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127918,"kind":"organization","name":"MILLENNIUM PHARMACEUTICALS INC","position":3,"cik":"0001002637","reported_name":"MILLENNIUM PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113074,"kind":"organization","name":"Takeda Ventures, Inc.","position":4,"cik":"0001771657","reported_name":"Takeda Ventures, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-09T06:04:25.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":128745,"price":18.43,"value":2372770.35,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average sale price.  This transaction was executed in multiple trades at prices ranging from $18.00 to $18.97.  Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc.  Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein."}],"balance_after":6288652,"source":{"system":"sec-edgar","filing":"0001395064-21-000248","document":"wf-form4_163904785164853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1002637/000139506421000248/wf-form4_163904785164853.xml","form_type":"4"}},{"id":2482965,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127918,"kind":"organization","name":"MILLENNIUM PHARMACEUTICALS INC","position":3,"cik":"0001002637","reported_name":"MILLENNIUM PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113074,"kind":"organization","name":"Takeda Ventures, Inc.","position":4,"cik":"0001771657","reported_name":"Takeda Ventures, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T06:01:34.000Z","date":"2021-12-06","kind":"sale","acquired":false,"shares":97692,"price":18.05,"value":1763340.6,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the weighted average sale price.  This transaction was executed in multiple trades at prices ranging from $18.00 to $18.27.  Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,360,173 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc.  Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein."}],"balance_after":6417397,"source":{"system":"sec-edgar","filing":"0001395064-21-000246","document":"wf-form4_163887488024165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1002637/000139506421000246/wf-form4_163887488024165.xml","form_type":"4"}},{"id":2482964,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127918,"kind":"organization","name":"MILLENNIUM PHARMACEUTICALS INC","position":3,"cik":"0001002637","reported_name":"MILLENNIUM PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113074,"kind":"organization","name":"Takeda Ventures, Inc.","position":4,"cik":"0001771657","reported_name":"Takeda Ventures, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T06:01:34.000Z","date":"2021-12-03","kind":"sale","acquired":false,"shares":12517,"price":18.47,"value":231188.99,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average sale price.  This transaction was executed in multiple trades at prices ranging from $18.10 to $18.78.  Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,360,173 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc.  Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein."}],"balance_after":6515089,"source":{"system":"sec-edgar","filing":"0001395064-21-000246","document":"wf-form4_163887488024165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1002637/000139506421000246/wf-form4_163887488024165.xml","form_type":"4"}},{"id":2493660,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127918,"kind":"organization","name":"MILLENNIUM PHARMACEUTICALS INC","position":3,"cik":"0001002637","reported_name":"MILLENNIUM PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":113074,"kind":"organization","name":"Takeda Ventures, Inc.","position":4,"cik":"0001771657","reported_name":"Takeda Ventures, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-29T17:16:15.000Z","date":"2021-11-24","kind":"other","acquired":true,"shares":57224,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 24, 2021, Takeda Ventures, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, received a distribution of 57,224 shares of Common Stock (the \"distribution\") from Atlas Venture Fund XI, L.P. Takeda Ventures, Inc. is a limited partner of Atlas Venture Fund XI, L.P. The distribution was a pro-rata distribution, and not a purchase or sale, without any consideration paid by Takeda Ventures, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of 6,470,382 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc.  Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein."}],"balance_after":6527606,"source":{"system":"sec-edgar","filing":"0001395064-21-000238","document":"wf-form4_163822415983916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1002637/000139506421000238/wf-form4_163822415983916.xml","form_type":"4"}},{"id":3361706,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":127918,"kind":"organization","name":"MILLENNIUM PHARMACEUTICALS INC","position":2,"cik":"0001002637","reported_name":"MILLENNIUM PHARMACEUTICALS INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-22T06:23:03.000Z","date":"2019-10-08","kind":"purchase","acquired":true,"shares":2000000,"price":2.5,"value":5000000.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Takeda Pharmaceutical Company Limited's beneficial ownership of the Issuer's Common Stock is comprised of 1,781,996 shares of Common Stock that it holds directly and 5,750,000 shares of Common Stock held directly by Millennium Pharmaceuticals, Inc., which is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (58.09%) and Takeda Pharmaceuticals International AG (41.91%).  Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited."}],"balance_after":5750000,"source":{"system":"sec-edgar","filing":"0001395064-19-000083","document":"wf-form4_157442176475523.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1002637/000139506419000083/wf-form4_157442176475523.xml","form_type":"4"}}]}